

PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 69139

Title: Hepatobiliar manifestations in inflammatory bowel disease: A practical approach

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04653160 Position: Peer Reviewer Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Ukraine

Author's Country/Territory: Chile

Manuscript submission date: 2021-06-18

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-07-17 15:50

Reviewer performed review: 2021-07-25 14:43

Review time: 7 Days and 22 Hours

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [] Minor revision [Y] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer	Peer-Review: [] Anonymous [Y] Onymous



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com **https:**//www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Some known hepatobiliary complications are omitted from the analysis. I mean portal hypertension and liver malignancies - cholangiocarcinoma and hepatocellular carcinoma. Actually, cholangiocarcinoma is considered to be the main dreath reason in IBD patients, so it MUST be included into analysis. Minor: 1. The common abbreviation of alkaline phosphatase is not AF but ALP (ALkaline Phosphatase) 2. Not all abbreviations are deciphered (p.10 BMI, p.11 HTN, p.13 FA, Fig.1 ALF, Table 1 TPMT)



PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 69139

Title: Hepatobiliar manifestations in inflammatory bowel disease: A practical approach

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05081677 Position: Peer Reviewer Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Greece

Author's Country/Territory: Chile

Manuscript submission date: 2021-06-18

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-07-20 09:45

Reviewer performed review: 2021-07-25 19:28

Review time: 5 Days and 9 Hours

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous



https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

It is a very well written narrative review about hepatobiliary manifestations in IBD. This review presents information about diagnosis and differential diagnosis of hepatic disorders in patients with IBD. Furthermore, the figures and tables are very useful. I would suggest the following revisions:

1) please add information about hepatotoxicity of thiopurines, methotrexate, corticosteroids and 5-ASA. Frequency rate of hepatotoxicity is significant by some of these medications
2) Please add information about hepatitis C and IBD
3) Please add information about IgG4-cholangiopathy and IBD



PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 69139

Title: Hepatobiliar manifestations in inflammatory bowel disease: A practical approach

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04168552 Position: Peer Reviewer Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Italy

Author's Country/Territory: Chile

Manuscript submission date: 2021-06-18

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-07-18 02:42

Reviewer performed review: 2021-07-26 09:15

Review time: 8 Days and 6 Hours

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com **https:**//www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

I read with great interest the narrative review titled "Hepatobiliar manifestations in inflammatory bowel disease: A practical approach." by Paulina Nunez et colleagues that summarize the IBD complications /comorbidities that afflict liver and cholecistis. article is well written and structured but deserve some minor revisions: INTRODUCTION I will add also dermatological complications since they are even more frequent than rheumatological comorbidities (i.e. hidradenitis suppurativa and psoriasis) (10.4254/wjh.v11.i4.391, 10.1155/2018/3140983) In this sentence"The autoimmune disease that is most frequently associated with IBD is primary sclerosing cholangitis (PSC), followed by autoimmune hepatitis (AIH) and overlap syndromes" please add also neutrophilic cholangitis (i.e.10.1007/s11739-017-1765-y) Please in this chapter "A) PRIMARY SCLEROSING CHOLANGITIS (PSC)" report also the differential diagnosis with neutrophilic cholangitis that remains often undiagnosed but is strictly related to an Please explain n this chapter "II. NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD)" also the different aethioogies of NAFLD and how frequent could be in case of IBD. Furthermore several drugs used for autoimmunity are capable to increase the occurrence [10.4254/wjh.v10.i2.329] Please table the biologics results to increase the readability.



PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 69139

Title: Hepatobiliar manifestations in inflammatory bowel disease: A practical approach

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05432221 Position: Editorial Board

Academic degree: DNB, FRCP, MBBS, MD, MRCP

Professional title: Associate Professor

Reviewer's Country/Territory: India

Author's Country/Territory: Chile

Manuscript submission date: 2021-06-18

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-07-16 16:58

Reviewer performed review: 2021-07-29 19:19

Review time: 13 Days and 2 Hours

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous



Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568 E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Thank you for reviewing and submitting to WJG. The review is written well but few points to be mentioned 1)Language polishing is necessary including few grammatical mistakes 2) More referencing is needed in Primary sclerosing cholangitis and IBD 3) Autoimmune sclerosing cholangitis as an entity should be mentioned 4) types of Auto immune Hepatitis need to be mentioned 5) A table should be provided with the gist of the texts with all types of Hepatobiliary manifestations 6)In the stepwise approach flow chart repeat LFT at what intervals? clarify how many times liver enzyme values? 'persistent' after how many tests?



RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Hepatology

Manuscript NO: 69139

Title: Hepatobiliar manifestations in inflammatory bowel disease: A practical approach

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04653160 Position: Peer Reviewer Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Ukraine

Author's Country/Territory: Chile

Manuscript submission date: 2021-06-18

Reviewer chosen by: Ji-Long Wang (Online Science Editor)

Reviewer accepted review: 2021-12-10 10:13

Reviewer performed review: 2021-12-11 22:15

Review time: 1 Day and 12 Hours

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No



SPECIFIC COMMENTS TO AUTHORS

As the reviewers' requirements have been addressed, the manuscript can be published